Disease · HP_0003326

Myalgia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Myalgia. Diseases, record HP_0003326. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0003326

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Myalgia; Open Targets
Open Targets ID: HP_0003326; Open Targets
Other names: Muscle ache, Muscle pain; Open Targets
NCI Thesaurus: C27009; NCI Thesaurus
Highest stage of its drugs: Approval, for 40 of its 59 drugs, from ATC and DailyMed; Open Targets

Drugs59

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IBUPROFEN	CHEMBL521	Small molecule	Approval	ATC	4	3	3	Drugs and targets
KETOPROFEN	CHEMBL571	Small molecule	Approval	ATC	3	2	1	Drugs and targets
METHYL SALICYLATE	CHEMBL108545	Small molecule	Approval	DailyMed	6	1	0	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Approval	ATC and DailyMed	6	0	0	Drugs and targets
MENTHOL	CHEMBL256087	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ACECLOFENAC	CHEMBL93645	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BENDAZAC	CHEMBL1089221	Small molecule	Approval	ATC	1	0	0	Drugs and targets
BENZYDAMINE	CHEMBL12610	Small molecule	Approval	ATC	1	0	0	Drugs and targets

1 to 10 of 59

See all 59 drugs

Targets74

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	19	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
PTGS1	Cyclooxygenase	17	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
TRPV1	Transient receptor potential cation channel subfamily V member 1	3	Vanilloid receptor agonist; Vanilloid receptor opener	Approval	https://conductscience.org/library/genes/7442	Drugs and targets
PGR	Progesterone receptor	2	Progesterone receptor agonist	Unknown	https://conductscience.org/library/genes/5241	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	2	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2	https://conductscience.org/library/genes/6616	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Unknown	https://conductscience.org/library/genes/7421	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1	https://conductscience.org/library/genes/136	Drugs and targets
ADORA3	Adenosine receptor	1	Adenosine receptor antagonist	Phase 1	https://conductscience.org/library/genes/140	Drugs and targets

1 to 10 of 74

See all 74 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04884763	Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder	Phase 2	30	2025-08-19	Temporomandibular Disorder	ERENUMAB	Its record names the disease	ClinicalTrials.gov
NCT01200069	IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia	Phase 4	14	2016-11-18	Depression, Myalgia	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT01022398	Vitamin D Replacement: The Effect on Statin-Related Myalgias	Not applicable	4	2013-05-20	HMG-CoA Reductase Inhibitors-related Myalgias	CHOLECALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT01373697	Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel	Phase 3	144		Muscular Atrophy, Sprains, Tendonitis	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT04847518	Assessment of Efficacy of KAN-JANG® in Mild COVID-19	Phase 2/3	140		Covid19	ELEUTHERO	Its record names the disease	ClinicalTrials.gov
NCT01140308	CoEnzyme Q10 in Statin Myopathy	Not applicable	135		Statin Myopathy	SIMVASTATIN, UBIDECARENONE	Its record names the disease	ClinicalTrials.gov
NCT02481193	Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia	Phase 3	90		Fasciculation	CISATRACURIUM	Its record names the disease	ClinicalTrials.gov
NCT01020279	Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise	Phase 1	82		Musculoskeletal Pain	CELECOXIB, KETOPROFEN	Its record names the disease	ClinicalTrials.gov
NCT06583551	Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia	Not applicable	80		Myalgia, Bruxism, Quality of Life	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT03037073	Duloxetine for Succinylcholine-induced Postoperative Myalgia	Phase 2/3	70		Postoperative Myalgia	DULOXETINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm A vs Arm B: deaths from any cause	0 of 15	0 of 15	30	NCT04884763	Trial comparisons
Arm A vs Arm B: serious adverse events	0 of 15	0 of 15	30	NCT04884763	Trial comparisons
Sugar Water vs Ibuprofen: serious adverse events	0 of 8	0 of 6	14	NCT01200069	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41070535	DERIVED	1	PubMed
39800961	DERIVED	1	PubMed
27993387	DERIVED	1	PubMed
25545331	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0003326

GET https://conductscience.org/api/diseases/v1/HP_0003326/drugs?page=2

API reference For AI assistants